Boston, MA 07/15/2013 (wallstreetpr) – The stock of MAKO Surgical Corporation (NASDAQ:MAKO) carries a Zacks Rank #2 indicating “Buy”, along with such companies as Cepheid and Edwards LifeSciences Corp, since these companies are likely to perform well. Companies that are expected to acquire Intuitive Surgical are twice more likely to acquire MAKO Surgical Corp given that, although MAKO Surgical Corp is currently non-profitable, the boom and bust cycle could act as the driving force because of its niche and effects of Obamacare. Management of MAKO Surgical Corp is another indicator for the intuitive heading to the next and keep everyone’s eyes fixed on July 18th report of intuitive.
More recently, MAKO Surgical Corp has made an announcement that Scott D. Flora and Jonathan T. Jack Lord have joined with the Board of Directors of the company. A substantial strategic value to the board of directors is brought by both Flora and Jack through their experience and previous successes. Currently, Mr. Flora is the President, Chief Executive Officer as well as one of the Directors of OmniGuide, Inc., which is a medical device company. Dr. Lord is the chairman of the directors’ board of Dexcom, Inc., which is also a medical device company.
MAKO Surgical Corp is a medical device company which is involved in the marketing of its Robotic Arm Interactive Orthopedic surgical platform, MAKOplasty, the RESTORIS implants and joint-specific applications for hip and knee. All of these together will enable the orthopedic surgeons to treat patient-specific osteo-arthritic disease in a consistent, reproductive and precise manner. The MAKOplasty incorporates the intellectual property portfolio enabled technologies which include over 300 US and foreign owned patents.
